MHRA Warns on Semaglutide Vision Risk | KIMS Hospitals ₹1000 Cr Milestone скачать в хорошем качестве

MHRA Warns on Semaglutide Vision Risk | KIMS Hospitals ₹1000 Cr Milestone

Welcome to HealthIQ Innovations – Healthcare & Pharma News Update 2026 In today’s episode, we cover three major developments shaping the global healthcare and pharmaceutical landscape: 🔹 MHRA Issues Safety Alert on Semaglutide The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has flagged an extremely rare risk of vision complications linked to semaglutide, commonly prescribed for type 2 diabetes and obesity management. Reports of non-arteritic anterior ischemic optic neuropathy (NAION) have prompted regulatory caution. While the risk remains very rare, clinicians are advised to counsel patients on reporting sudden vision changes. 🔹 KIMS Hospitals Crosses ₹1,000 Crore Quarterly Revenue KIMS achieves a historic financial milestone, driven by rising patient volumes, operational efficiencies, and expansion in tertiary and quaternary care services. This reflects the strong growth trajectory of India's hospital sector. 🔹 Wanbury Q3 Profit Surge Pharmaceutical company Wanbury reports a sharp increase in net profit and operating margins, fueled by strong API demand, better capacity utilization, and cost optimization strategies. 📌 Key Topics Covered: Semaglutide safety update NAION and vision loss risk MHRA regulatory advisory Indian hospital sector growth KIMS quarterly results Pharmaceutical API market trends Wanbury financial performance Healthcare industry news 2026 This update highlights how patient safety, hospital expansion, and pharmaceutical growth are collectively shaping the future of medicine and life sciences. Subscribe for credible healthcare insights, pharma market analysis, and regulatory updates. #HealthcareNews #PharmaNews #Semaglutide #MHRA #DiabetesCare #HospitalIndustry #KIMSHospitals #Wanbury #APIIndustry #MedicalUpdates #HealthIQ #LifeSciences #HealthcareInnovation